2 small biotech firms with big potential

The biotechnology sector continues to offer interesting investment propositions.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Innovative pharmaceutical business Acrux (ASX: ACR) recently signed a distribution deal in Brazil for its flagship testosterone deficiency drug Axiron. The drug can improve sex drive and energy levels in men, and is particularly popular in the billion-dollar U.S market.

Approval for sale in Brazil follows on from recent approval in Germany and Acrux has identified 142 countries with potential for the drug's distribution. 2010 was Acrux's breakthrough year, after it received approval to market Axiron from the U.S Food and Drug Administration (FDA). It recently had that patent extended until 2027.

The innovative aspect of the Acrux business is that it develops drugs that can be administered topically through the skin in simple spray or liquid form. This is an increasingly patient-preferred method, rather than less convenient methods like injection.

Acrux is also in the process of commercialising Estradiol, a spray therapy for female menopause symptoms. The company has a market cap around $420 million and shows how the biotech sector can deliver big profits for shareholders who get in early enough.

Another small-cap biotechnology company gaining publicity recently is Prana Biotechnology (ASX PBT). It's attempting to develop treatments for some of the world's most common diseases, in particular Alzheimer's and Parkinson's. Success has blockbuster potential for shareholders, with the company expected to release the results of its latest Alzheimer's drug trials in March 2014.

In the last year, shares in the business have tripled in value then almost halved again as investors speculate on the company's success in developing and commercialising the Alzheimer's drugs. Eventual U.S FDA approval for any Alzheimer's treatment is the Holy Grail, but that's a long way off yet, with the company giving no further clues as to the status of the trials after its AGM last week. Even reported trial success is absolutely no guarantee of FDA approval to market the drugs.

Current market cap is $216 million, although investors can expect this to gyrate sharply as the results of its drug trials become clearer.

Foolish takeaway

Regulatory approval for a company's drug treatment in the world's largest healthcare market can be like winning the lottery for a company and its shareholders. Acrux's recent success a modest example. Any investment in Prana is highly speculative, with the news flow now driving the share price. If investors are to try and chase the next big thing, they should be sensitive of the sometimes dubious nature of that news flow.

Motley Fool contributor Tom Richardson owns share in Prana Biotechnology. 

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »